Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114


Prior aspirin use and outcomes in acute coronary syndromes.

Rich JD, Cannon CP, Murphy SA, Qin J, Giugliano RP, Braunwald E.

J Am Coll Cardiol. 2010 Oct 19;56(17):1376-85. doi: 10.1016/j.jacc.2010.06.028.


Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.

CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S.

N Engl J Med. 2010 Sep 2;363(10):930-42. doi: 10.1056/NEJMoa0909475. Erratum in: N Engl J Med. 2010 Oct 14;363(16):1585.


Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.

Ambrosio G, Steinhubl S, Gresele P, Tritto I, Zuchi C, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Mehran R, Stone GW.

Eur J Cardiovasc Prev Rehabil. 2011 Feb;18(1):121-8. doi: 10.1097/HJR.0b013e32833bc070.


Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.

Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF; DISPERSE-2 Investigators.

J Am Coll Cardiol. 2007 Nov 6;50(19):1844-51. Epub 2007 Oct 23. Erratum in: J Am Coll Cardiol. 2007 Nov 27;50(22):2196.


Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.

Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P, Yusuf S; CURRENT-OASIS 7 Steering Committee.

Am Heart J. 2008 Dec;156(6):1080-1088.e1. doi: 10.1016/j.ahj.2008.07.026. Epub 2008 Nov 1.


Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.

Bonello L, De Labriolle A, Lemesle G, Steinberg DH, Roy P, Torguson R, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R.

Catheter Cardiovasc Interv. 2009 Jun 1;73(7):866-70. doi: 10.1002/ccd.21935.


Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective.

Bhattacharya R, Pani A, Dutta D, Basak S, Gangopadhyay S, Das Baksi S, Sarkar RN.

Singapore Med J. 2010 Jul;51(7):558-64.


Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.

Feldman DN, Minutello RM, Bergman G, Moussa I, Wong SC.

Catheter Cardiovasc Interv. 2010 Oct 1;76(4):513-24. doi: 10.1002/ccd.22546.


Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial.

Collet JP, Montalescot G, Steg PG, Steinhubl SR, Fox KA, Hu TF, Johnston SC, Hamm CW, Bhatt DL, Topol EJ.

Arch Cardiovasc Dis. 2009 Jun-Jul;102(6-7):485-96. doi: 10.1016/j.acvd.2009.03.012. Epub 2009 Jun 11.


Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.

Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin L; PLATO Study Group.

Circulation. 2010 Nov 23;122(21):2131-41. doi: 10.1161/CIRCULATIONAHA.109.927582. Epub 2010 Nov 8.


Chronic aspirin and statin therapy in patients with impaired renal function and acute coronary syndromes: results from the IN-ACS Outcome Registry.

Sciahbasi A, Rizzello V, Gonzini L, Giampaoli S, Greco C, Di Pasquale G, Mureddu GF, Di Chiara A, Lioy E, Boccanelli A.

Eur J Prev Cardiol. 2014 Feb;21(2):214-21. doi: 10.1177/2047487312460021. Epub 2012 Sep 5.


A risk score to predict bleeding in patients with acute coronary syndromes.

Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW.

J Am Coll Cardiol. 2010 Jun 8;55(23):2556-66. doi: 10.1016/j.jacc.2009.09.076.


Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry.

Shaw LJ, Shaw RE, Merz CN, Brindis RG, Klein LW, Nallamothu B, Douglas PS, Krone RJ, McKay CR, Block PC, Hewitt K, Weintraub WS, Peterson ED; American College of Cardiology-National Cardiovascular Data Registry Investigators.

Circulation. 2008 Apr 8;117(14):1787-801. doi: 10.1161/CIRCULATIONAHA.107.726562. Epub 2008 Mar 31.


Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.

Heer T, Juenger C, Gitt AK, Bauer T, Towae F, Zahn R, Senges J, Zeymer U; Acute Coronary Syndromes (ACOS) Registry Investigators.

J Thromb Thrombolysis. 2009 Oct;28(3):325-32. doi: 10.1007/s11239-008-0294-y. Epub 2008 Dec 20.


Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes.

Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R, Beygui F, Payot L, Vignolles N, Metzger JP, Thomas D.

Circulation. 2004 Oct 19;110(16):2361-7. Epub 2004 Oct 11.


Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L.

Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003.


Early versus delayed, provisional eptifibatide in acute coronary syndromes.

Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators.

N Engl J Med. 2009 May 21;360(21):2176-90. doi: 10.1056/NEJMoa0901316. Epub 2009 Mar 30.


[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].

Pevzner DV, Staroverov II, Samko AN, Frolova NS, Mazurov AV, Ruda MY.

Kardiologiia. 2010;50(6):22-6. Russian.


Fine-tuning therapy for acute coronary syndromes.

Fuster V.

N Engl J Med. 2010 Sep 2;363(10):976-7. doi: 10.1056/NEJMe1008891. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk